Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31884Editorial articleПередовая статьяReview ArticleThe etiopathogenetic bases for antibacterial therapy and prevention of urinary tract infectionsЭтиопатогенетические основы антибактериальной терапии и профилактики инфекций мочевых путейKayukovI GКаюковИ Г«Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава Росси151120158711VOL 87, NO11 (2015)ТОМ 87, №11 (2015)12313310042020Copyright ©; 2015, Consilium MedicumCopyright ©; 2015, ООО "Консилиум Медикум"2015Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31884

The paper discusses the pathogenesis of urinary tract infections, the mechanisms of resistance in their pathogens to antimicrobials and uroseptics, and approaches to defining patient management tactics.

В статье обсуждается патогенез инфекций мочевых путей, механизмы формирования устойчивости их возбудителей к антибактериальным препаратам и уросептикам, подходы к определению тактики ведения больных.

urinary tract infectionsetiologypathogenesistreatmentpreventionинфекции мочевых путейэтиологияпатогенезлечениепрофилактикаПалагин И.С. Современные аспекты выбора антимикробных препаратов при острых неосложненных циститах. Клиническая микробиология и антимикробная химиотерапия. 2009;11(4):327-334.Ушкалова Е.А. Фторхинолоны в лечении инфекций мочевыводящих путей: современное состояние вопроса. Фарматека. 2005;16. Доступно по: http://www.medvestnik.ru/library/article/6306.Ejrnæs K. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Dan Med Bull. 201;58(4):B4187.Hisano M, Bruschini H, Nicodemo AC, Srougi M. Cranberries and lower urinary tract infection prevention. Clinics (Sao Paulo). 2012;67(6):661-668.Синякова Л.А., Косова И.В. Антимикробная терапия неосложненных инфекций мочевых путей. Consilium Medicum. 2014;7:29-33.Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49(2):53-70.Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010 362(19):1804-1813.Лоран О.Б. Эпидемиологические аспекты инфекций мочевыводящих путей. Материалы международного симпозиума «Инфекции мочевыводящих путей у амбулаторных больных». М.; 1999:5-8.Лопаткин Н.А., Мартов А.Г. Состояние и перспективы развития урологической помощи в Российской федерации. Материалы X Всероссийского съезда урологов. М.; 2002:5-30. Доступно по: www.uro.ru/society)Rice LB. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc. 2012;87(2):198-208.Asadi S, Kargar M, Solhjoo K, Najafi A, Ghorbani-Dalini S. The association of virulence determinants of uropathogenic Escherichia coli with antibiotic resistance. Jundishapur J Microbiol. 2014;7(5):e9936. doi:10.5812/jjm.9936.Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250-259.Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128-112.Linhares I. Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000—2009). BMC Infect Dis. 2013;13:19. doi:10.1186/1471-2334-13-19.Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health. 2013;10(12):6235-6254.Grabe M, Bartoletti R, Bjerklund-Johansen TE, Cai T, Çek M, Köves B, Naber KG, Pickard RS, Tenke P, Wagenlehner F, Wullt B. Guidelines on Urological Infections European Association of Urology. Urol Infect. 2011;5(5):316-332. doi:10.5489/cuaj.11214.Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103-120.Российские национальные рекомендации «Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов» 2015. Под ред. Аполихина О.И., Пушкарь Д.Ю., Камалова А.А., Перепановой Т.С. М.; 2015.Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005;71(5):933-942.Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol. 2008;6(1):17-27.Mu XQ, Bullitt E. Structure and assembly of P-pili: a protruding hinge region used for assembly of a bacterial adhesion filament. Proc Natl Acad Sci USA. 2006;103(26):9861-9866.Garofalo CK, Hooton TM, Martin SM, Stamm WE, Palermo JJ, Gordon JI, Hultgren SJ. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect Immun. 2007;75(1):52-60.Russo TA, Stapleton A, Wenderoth S, Hooton TM, Stamm WE. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J Infect Dis. 1995;172(2):440-445.Manges AR, Tabor H, Tellis P, Vincent C, Tellier PP. Emerg Infect Dis Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections. 2008;14(10):1575-1583.Foxman B, Manning SD, Tallman P, Bauer R, Zhang L, Koopman JS, Gillespie B, Sobel JD, Marrs CF.Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am J Epidemiol. 2002;156(12): 1133-1140.Erhardt M, Namba K, Hughes KT. Bacterial nanomachines: the flagellum and type III injectisome. 2010 Cold Spring Harb Perspect Biol 2010. doi:10.1101/cshperspect.a000299 originally published online.Duan Q, Zhou M, Zhu L, Zhu G. Flagella and bacterial pathogenicity. J Basic Microbiol. 2013;53(1):1-8. doi:10.1002/jobm.201100335.Macnab RM. The bacterial flagellum: reversible rotary propellor and type III export apparatus. J Bacteriol. 1999;181(23): 7149-7153.Chatterjee S, Chaudhury S, McShan AC, Kaur K, De Guzman RN. Structure and biophysics of type III secretion in bacteria. Biochemistry. 2013;52(15):2508-2517.Büttner D. Protein export according to schedule: architecture, assembly, and regulation of type III secretion systems from plant- and animal-pathogenic bacteria. Microbiol Mol Biol Rev. 2012;76(2):262-310.Lane MC, Alteri CJ, Smith SN, Mobley HL. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci USA. 2007;104(42):16669-16674.Hazelbauer G, Falke J, Parkinson J. Bacterial chemorecep-tors: high-performance signaling in networked arrays. Trends in Biochemical Sciences. 2008;33(1):9-19.Tu Y. Quantitative modeling of bacterial chemotaxis: signal amplification and accurate adaptation. Annu Rev Biophys. 2013;42: 337-359.Alteri CJ, Mobley HL. Escherichia coli physiology and metabolism dictates adaptation to diverse host microenvironments. Curr Opin Microbiol. 2012;15(1):3-9.Silverman JA, Schreiber HL 4th, Hooton TM, Hultgren SJ. From physiology to pharmacy: developments in the pathogenesis and treatment of recurrenturinary tract infections. Curr Urol Rep. 2013;14(5):448-456.Hacker J, Blum-Oehler G, Mühldorfer I, Tschape H. Pathogenicity islands of virulent bacteria: structure, function and impact on microbial evolution. Mol Microbiol. 1997;23:1089-1097.Johnson JR, Kuskowski MA, Gajewski A, Soto S, Horcajada JP, Jimenez de Anta MT, Vila J. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis. 2005;191:46-50.Lloyd AL, Rasko DA, Mobley HL. Defining genomic islands and uropathogen-specific genes in uropathogenic Escherichia coli. J Bacteriol. 2007;189:3532-3546.Vandewalle A. Toll-like receptors and renal bacterial infections. Chang Gung Med J. 2008;31(6):525-537.Robson MG. Toll-like receptors and renal disease. Nephron Exp Nephrol. 2009;113(1):e1-7.Ben Mkaddem S, Chassin C, Vandewalle A. Contribution of renal tubule epithelial cells in the innate immune response during renal bacterial infections and ischemia-reperfusion injury. Chang Gung Med J. 2010;33(3):225-240.Gonçalves GM, Castoldi A, Braga TT, Câmara NO. New roles for innate immune response in acute and chronic kidney injuries. Scand J Immunol. 2011;73(5):428-435.Сидоренко С.В. Фторхинолоны: свойства и клиническое применение. Трудный пациент. 2011;5:21-27.Березняков И.Г. Клиническое значение выработки β-лактамаз и подходы к решению проблемы. Болезни и антибиотики. 2012;1(6). Доступно по: http://www.mif-ua.com/archive/issue-29339/Wagenlehner FM, Naber KG. Treatment of bacterial urinary tract infections: presence and future. Eur Urol. 2006;49(2):235-244.Rafalsky V, Andreeva I, Rjabkova E. Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev. 2006;3:CD003597.Zalmanovici Trestioreanu A, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev. 2010;10:CD007182.Katchman EA, Milo G, Paul M, Christiaens T, Baerheim A, Leibovici L. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. Am J Med. 2005;118(11):1196-1207.Nicolle LE. Short-term therapy for urinary tract infection: success and failure. Int J Antimicrob Agents. 2008;31(Suppl.1):S40-S45.